| Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. | |
| | |
MedLine Citation:
|
PMID: 12162466 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Coronary heart disease (CHD) is the leading cause of morbidity and mortality in the Western world, with hypercholesterolemia as the major risk factor. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors represent the most efficient drugsfor the treatment of hypercholesterolemia. They lower plasma cholesterol due to the inhibition of endogenous cholesterol synthesis in the liverand subsequent increased expression of low-density lipoprotein (LDL) receptors, resulting in an up-regulated catabolic rate for plasma LDL. The beneficial effect of statins on the incidence of CHD was clearly demonstrated in several large-scale clinical trials. Currently, five statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) are available, and two novel compounds (pitavastatin, rosuvastatin) are undergoing clinical investigation. To point out potential mechanisms leading to increased toxicity and to compare the novel statins with the established ones, this article summarizes their pharmacological data since the prevalence of adverse events can be explained at least in part by their pharmacokinetic differences. |
| | |
Authors:
|
Michael Igel; Thomas Sudhop; Klaus von Bergmann |
Related Documents
:
|
10684406 - A comparison of the tolerability and efficacy of lovastatin 20 mg and fluvastatin 20 mg... 19694216 - Simvastatin increases clot permeability and susceptibility to lysis in patients with ld... 17192126 - Intensive reduction of low-density lipoprotein-cholesterol: implications of recent trials. 12201566 - A randomized, double-blind comparison of cerivastatin and lovastatin for treatment of p... 20150186 - Early hepatic insulin resistance in mice: a metabolomics analysis. 16364276 - Postprandial lipemic response and lipoprotein composition in subjects with low or high ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Journal of clinical pharmacology Volume: 42 ISSN: 0091-2700 ISO Abbreviation: J Clin Pharmacol Publication Date: 2002 Aug |
Date Detail:
|
Created Date: 2002-08-06 Completed Date: 2003-02-21 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0366372 Medline TA: J Clin Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 835-45 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacology, University of Bonn, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acyl Coenzyme A
/
antagonists & inhibitors*,
metabolism Antilipemic Agents / adverse effects, pharmacokinetics, pharmacology, therapeutic use Coronary Disease / drug therapy Enzyme Inhibitors / adverse effects, pharmacokinetics, pharmacology*, therapeutic use Fluorobenzenes / adverse effects, pharmacokinetics, pharmacology*, therapeutic use Pyrimidines* Quinolines / adverse effects, pharmacokinetics, pharmacology*, therapeutic use Sulfonamides* |
| Chemical | |
Reg. No./Substance:
|
0/Acyl Coenzyme A; 0/Antilipemic Agents; 0/Enzyme Inhibitors; 0/Fluorobenzenes; 0/Pyrimidines; 0/Quinolines; 0/Sulfonamides; 147526-32-7/NK 104; 1553-55-5/3-hydroxy-3-methylglutaryl-coenzyme A; 287714-41-4/rosuvastatin |
| Comments/Corrections | |
Erratum In:
|
J Clin Pharmacol. 2003 Sep;43(9):1015 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phospholipase D/phosphatidic acid signal transduction: role and physiological significance in lung.
Next Document: Risk assessment in regulatory policy making for human and veterinary public health.